-
Serious Adverse Health Events Associated with Methanol-based Hand Sanitizers
7/4/20 On June 19, 2020, the U.S. Food and Drug Administration (FDA) advised consumers not to use any hand sanitizer manufactured by “Eskbiochem SA de CV” in Mexico, due to the potential presence of methanol, a “toxic alcohol”, as an active ingredient, which can cause blindness and/or death when absorbed through the skin or when swallowed.
-
COVID-19 & Respiratory Tools: How to Access, Use and Clean Inhalers & Nebulizers
6/30/20 Board-certified allergist Pfrom the Allergy & Asthma Network, will discuss the use of inhalers and nebulizers during the COVID-19 outbreak.
-
State announces findings in study of virus-related pediatric inflammatory syndrome
6/29/20 State health officials on Monday announced the findings of a study on the pediatric multisystem inflammatory syndrome associated with Covid-19.
-
FDA Approves Tandem’s t:slim X2 Insulin Pump with Control-IQ for Children Age 6 and Up
6/28/20 The U.S. FDA has announced clearance of an expanded pediatric indication for the Tandem’s t:slim X2™ insulin pump with Control-IQ™ technology to children age 6 and older. The product was previously approved for ages 14 and older. Control-IQ technology is an advanced hybrid closed-loop feature designed to increase time in range (70-180 mg/dL).
-
Low-dose fenfluramine (Fintepla), Approved to Treat Seizures Associated with Dravet Syndrome in Those Age 2 and Older
6/27/20 The FDA announced that low-dose fenfluramine (Fintepla), a Schedule IV controlled substance, was approved to treat seizures associated with Dravet syndrome in patients age 2 and older. Dravet syndrome is a rare, life-threatening form of epilepsy often characterized by intractable seizures.
